ICU Cases · Statistics & evidence
Appraising the ACURASYS-vs-ROSE contradiction
A long case on the appraisal of two contradictory trials — the ACURASYS (NMBA benefit) and the ROSE (no benefit), and the methodological reasons the ROSE overturned the ACURASYS.
On this page
Study tools
Target exams
CICMFFICMEDIC
Prompt
A long case on the appraisal of two contradictory trials — the ACURASYS (NMBA benefit) and the ROSE (no benefit), and the methodological reasons the ROSE overturned the ACURASYS.
Presentation
A colleague cites the ACURASYS trial (the NEJM 2010) to support the routine 48-hour cisatracurium in the severe ARDS. Appraise the ACURASYS and the ROSE and reconcile.[4]
References3ShowHide
- [4]Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome (ACURASYS). New England Journal of Medicine, 2010.PMID 20843245
- [5]Moss M, Huang DT, Brower RG, et al. Early Neuromuscular Blockade in the Acute Respiratory Distress Syndrome (ROSE). New England Journal of Medicine, 2019.PMID 31112383
- [9]Bersten AD, Soni N (eds) Oh's Intensive Care Manual. 8th edition, Elsevier, 2018.